1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Jinghua Pharmaceutical Group Co., Ltd.

Jinghua Pharmaceutical Group Co., Ltd.

002349.SZ
Jinghua Pharmaceutical Group Co., Ltd.CN flagShenzhen Stock Exchange
6.50
CNY
-NaN
- -
5.40BMarket Cap
Jinghua Pharmaceutical Group Co., Ltd.
002349.SZ
(Shenzhen Stock Exchange)

Recent

price

6.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.47
0.63
1.11
1.22
0.96
0.99
1.05
1.33
1.63
1.42
1.57
1.67
1.93
1.86
1.72
1.78
1.74
Revenue per Share
0.07
0.08
0.08
0.06
0.07
0.1
0.2
0.21
0.28
-0.48
0.14
0.2
0.26
0.3
0.26
0.27
0.26
Basic EPS, GAAP
0.01
-0.1
-0.19
-0.19
0.03
-0.17
0.12
-0.43
-0.09
0.04
0.26
0.28
0.36
0.32
0.34
0.39
-0.02
Free Cash Flow per Basic Share
0.01
0.01
0.02
0.03
0.02
0.04
0.04
0.08
0.07
0.07
0.02
0.05
0.07
0.08
0.09
0.08
0.08
Dividend per Share
0.27
0.35
0.58
0.61
0.76
0.66
0.94
1.57
1.78
1.29
1.41
1.55
1.71
1.91
2.06
2.24
2.16
Book Value per Share
0.91
1.01
0.95
1
2.28
1.88
1.81
2.23
2.27
2.2
2.66
2.77
2.94
3.16
3.35
3.57
3.44
Tangible Book Value per Share
587
600
600
600
600
785
840
840
833
814
814
814
814
814
814
819
814
Basic Weighted Avg Shares
274
376
665
733
578
780
881
1,121
1,355
1,157
1,281
1,358
1,573
1,512
1,402
1,460
1,413
Sales/Revenue/Turnover
18.23
10.72
6.99
6.92
8.25
11.32
19.98
24.43
23.53
11.66
19.66
14.11
14.97
20.55
18.61
19.48
18.96
Operating Margin (%)
9
9
17
25
40
46
60
64
78
81
84
102
110
85
77
81
- -
Depreciation Expense
43
48
49
36
39
78
165
175
230
-394
111
161
212
248
213
219
208
Net Income, GAAP
15.03
15.43
17.31
5.02
20.48
15.39
14.12
12.22
9.84
- -
56.19
21.76
15.16
16.14
15.63
13.76
14.58
Effective Tax Rate (%)
15.54
12.81
7.4
4.86
6.83
10.01
18.72
15.64
16.95
-34.01
8.66
11.83
13.49
16.38
15.17
15.02
14.71
Profit Margin (%)
455
475
288
264
944
787
655
918
745
548
891
992
1,334
1,624
1,519
1,632
1,496
Working Capital
- -
- -
- -
- -
3
1
- -
240
180
220
125
4
1
- -
- -
2
- -
LT Debt
544
636
715
742
1,535
2,234
2,303
2,647
2,695
2,148
2,487
2,570
2,624
2,804
2,957
3,149
3,031
Total Equity
11.86
5.74
5.59
6.19
3.05
3.72
6.47
9.12
9.5
- -
4.3
5.73
7.85
10.06
7.99
8.18
7.88
Return on Invested Capital (%)
29.83
22.9
11.33
6.9
6.73
9.91
17.7
11.22
9.73
- -
10.99
10.57
12.72
12.37
8.94
8.24
8.3
Return on Capital (%)
32.67
26.23
17.65
9.97
9.61
16
25.15
16.65
16.43
-31.15
10.1
13.32
16
16.8
13.14
12.48
12.31
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
11
10
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
814
814
830
Market Capitalization
6,229
5,888
5,855

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
1,844
1,930
1,871
Cash, Cash Equivalents & STI
1,119
1,183
1,085
Accounts Receivable, Net
291
312
323
Inventories
270
272
282
Total Current Liabilities
326
326
375
Payables & Accruals
- -
- -
- -
ST Debt
11
10
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.96%
4.85%
6.5%
Free Cash Flow
-21.42%
9.75%
14.44%
Net Income, GAAP
-16.85%
16.5%
3.12%
Sales/Revenue/Turnover
7.19%
2.96%
4.13%
Total Cash Common Dividend
21.85%
33.48%
-13.64%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
367
353
325
357
1,402
2025
364
368
368
- -
1,460
2026
380
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.09
- -
- -
- -
0.26
2025
0.08
- -
- -
- -
0.27
2026
0.08
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.09
2025
- -
- -
- -
- -
0.08
2026
- -
- -
- -
- -
- -
Similar Companies
Amrutanjan Health Care Limited (AMRUTANJAN.BO)
Ilsung Is Co., Ltd. (003120.KS)
Jeil Pharmaceutical Co.,Ltd (271980.KS)
Amphastar Pharmaceuticals, Inc. (AMPH)
Shanghai Kaibao Pharmaceutical CO.,Ltd (300039.SZ)
Guardion Health Sciences, Inc. (GHSI)
Business
Jinghua Pharmaceutical Group Co., Ltd. engages in the research, development, production, and sale of traditional Chinese patent medicine preparations, chemical active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and Chinese herbal medicines in China. Its product portfolio includes more than 200 types of Chinese and Western medicines, with core products comprising APIs such as Phenobarbital, Primidone, Fluorouracil, Phenylbutazone, Propylthiouracil, Piroxicam, Flucytosine, and various traditional Chinese medicine tablets and preparations like Wang's Baochi Pills, Ji Desheng Snake Pills, and Zheng Chai Hu Drink Granules. Jinghua Pharmaceutical maintains GMP certification and complies with Chinese Pharmacopoeia, European Pharmacopoeia, British Pharmacopoeia, and USP standards, with several APIs having obtained Certificate of Suitability and US FDA approvals. Founded in 1957 and headquartered in Nantong, China, the company operates primarily in the Chinese pharmaceutical market, emphasizing both chemical and traditional medicine segments. Recent major developments include Jinghua Pharmaceutical's strategic acquisition plans, notably the pending acquisition of Alpha Pharmaceutical for approximately $165 million, representing a significant expansion of its pharmaceutical production capacity and product offerings. The company has also secured multiple new drug registration certificates and medical device registration approvals in 2024, including for its medical sodium alginate wound dressing, reflecting its ongoing product innovation in both pharmaceuticals and medical devices. Additionally, Jinghua has strengthened its corporate structure through updated industrial and commercial registrations and newly implemented investment and financial management systems to support its expanding operations. These strategic moves signify Jinghua Pharmaceutical's intent to consolidate its market position and broaden its product range in both APIs and proprietary Chinese medicines within China and potentially beyond. This multifaceted pharmaceutical group serves a diverse customer base including hospitals, clinics, pharmaceutical distributors, and traditional medicine markets across China. It is recognized as a government-oriented enterprise with a strong commitment to safe, effective, and stable medicine production, supported by a comprehensive quality assurance framework. Jinghua Pharmaceutical's long-standing industry presence and recent operational enhancements position it as a significant player in China's pharmaceutical landscape.